NEWRON PHARMACEUTICALS
Newron Pharmaceuticals S.p.A. is a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central and peripheral nervous system. Xadago® (safinamide) has received marketing authorization for the treatment of Parkinson’s disease in the European Union, Switzerland and the USA, and is commercialized by Newron’s Partner Zambon. US WorldMeds holds the commercialization rights in the USA. Meiji Seika, in collaboration with Eisai, has the rights ... to develop and commercialize the compound in Japan and other key Asian territories. In addition to Xadago® for Parkinson’s disease, Newron has a strong pipeline of promising treatments for rare disease patients at various stages of clinical development, including sarizotan for patients with Rett syndrome and ralfinamide for patients with specific rare pain indications. Newron is also developing Evenamide as the potential first add-on therapy for the treatment of patients with positive symptoms of schizophrenia. Founded in 1999, Newron is headquartered in Bresso, near Milan, Italy, with a subsidiary in Morristown, NJ, USA. The Company is listed on the SIX Swiss Exchange, trading symbol NWRN.
NEWRON PHARMACEUTICALS
Social Links:
Industry:
Biopharma Biotechnology Health Care Medical
Founded:
1999-01-01
Address:
Bresso, Lombardia, Italy
Country:
Italy
Website Url:
http://www.newron.com
Total Employee:
11+
Status:
Active
Contact:
+39026103461
Email Addresses:
[email protected]
Total Funding:
129.43 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Content Delivery Network Font Awesome Domain Not Resolving Microsoft Exchange Online Amazon Office 365 Mail
Similar Organizations
Accent Therapeutics
Accent Therapeutics is a biopharmaceutical company.
Context Therapeutics
Context Therapeutics is a clinical-stage biopharmaceutical company.
Enterin
Philadelphia-based biotechnology company .
Faron Pharmaceuticals
Faron Pharmaceuticals is a biopharmaceutical company engaged in the biotechnology and medical research industry.
Jenrin Discovery
Jenrin Discovery is a biopharmaceutical Company.
Minerva Neuroscience
Minerva Neurosciences is a clinical-stage biopharmaceutical company
Ocugen
Ocugen is a clinical stage biopharmaceutical company.
Current Advisors List
Current Employees Featured
Founder
Stock Details
Acquisitions List
| Date | Company | Article | Price |
|---|---|---|---|
| 2012-06-13 | NeuroNova | NeuroNova acquired by Newron Pharmaceuticals | N/A |
| 2008-02-11 | Hunter-Fleming Ltd | Hunter-Fleming Ltd acquired by Newron Pharmaceuticals | N/A |
Investors List
TVM Capital
TVM Capital investment in Series B - Newron Pharmaceuticals
3i Group
3i Group investment in Series B - Newron Pharmaceuticals
HBM Partners
HBM Partners investment in Series B - Newron Pharmaceuticals
Apax Partners
Apax Partners investment in Series B - Newron Pharmaceuticals
Atlas Venture
Atlas Venture investment in Series B - Newron Pharmaceuticals
Apax Partners
Apax Partners investment in Venture Round - Newron Pharmaceuticals
3i Group
3i Group investment in Venture Round - Newron Pharmaceuticals
Atlas Venture
Atlas Venture investment in Venture Round - Newron Pharmaceuticals
3i Group
3i Group investment in Venture Round - Newron Pharmaceuticals
Official Site Inspections
http://www.newron.com Semrush global rank: 3.25 M Semrush visits lastest month: 5.08 K
- Host name: ec2-52-17-142-199.eu-west-1.compute.amazonaws.com
- IP address: 52.17.142.199
- Location: Dublin Ireland
- Latitude: 53.3338
- Longitude: -6.2488
- Timezone: Europe/Dublin
- Postal: D02
More informations about "Newron Pharmaceuticals"
Homepage | Newron Pharmaceuticals
Newron Pharmaceuticals S.p.A. is a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central and peripheral nervous system. …See details»
Investors - Newron Pharmaceuticals
Mar 11, 2025 Newron is committed to providing reliable and transparent information about our business in an open and timely manner. This area contains investment and shareholder …See details»
Annual Report 2023 - Newron Pharmaceuticals
Newron Pharmaceuticals S.p.A. has four fully owned subsidiaries (collectively, “Newron Group”): Newron Pharmaceuticals US, Inc., is a U.S. limited liability company, incorporated under the …See details»
Newron Pharmaceuticals - Crunchbase Company Profile & Funding
Newron Pharmaceuticals S.p.A. is a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central and peripheral nervous system. …See details»
Newron proposes renowned biopharma company founder and …
Mar 24, 2025 MILAN & MORRISTOWN, N.J., March 24, 2025--Newron proposes renowned biopharma company founder and entrepreneur Dr. Chris Martin for election as Independent …See details»
Newron Pharmaceuticals S.p.A. - Devex
Learn more about Newron Pharmaceuticals S.p.A.'s jobs, projects, latest news, contact information and geographical presence. Newron Pharmaceuticals S.p.A. is a …See details»
Newron Pharmaceuticals - Funding, Financials, Valuation & Investors
In funding over 10 rounds. Their latest funding was raised on Sep 26, 2017 from a Post-IPO Equity round. Newron Pharmaceuticals is registered under the ticker SIX:NWRN . Newron …See details»
Organization | Newron Pharmaceuticals
Newron Pharmaceuticals Report issue Contributed to NMEFor profit Phase 2 Phase 3 Founded: Bresso Lombardia Italy (1998) Organization Overview First Clinical Trial 2004 NCT00736151 …See details»
Newron Pharmaceuticals S.p.A.: Governance, Directors and …
Dec 31, 2013 Find the composition of the Board of Directors of Newron Pharmaceuticals S.p.A. (BOERSE MUENCHEN Stock Exchange), the gender parity as well as the age distribution of …See details»
News at Newron Pharmaceuticals - The Official Board
Newron Pharmaceuticals: See the recent changes among its 10 executives.See details»
Newron Pharmaceuticals - Craft
Oct 29, 2024 Newron Pharmaceuticals is a biopharmaceutical company focused on the discovery and development of drugs for the treatment of central nervous system disorders and …See details»
Governance | Newron Pharmaceuticals
Newron's Board of Directors (the "Board") and management are committed to high standards of corporate governance, including transparency and accountability towards its shareholders as …See details»
Newron Pharmaceuticals - Edison Group
Newron Pharmaceuticals is focused on the central nervous system. Xadago for Parkinson’s disease (PD) is sold in Europe, Japan, the United States and other regions. Evenamide, a …See details»
NEWRON - Crunchbase Company Profile & Funding
NEWTON is a consulting agency that provides ideation planning, incubation program management, and marketing HR training services.See details»
Newron Extends Senior Management Team and Strengthens
Jul 1, 2022 Newron extends Senior Management team and strengthens its commitment to ESG by appointing Filippo Moriggi as Vice President of Operations.See details»
Newron Pharmaceuticals - Products, Competitors, Financials, …
Nov 27, 2006 Investors of Newron Pharmaceuticals include Atlas Venture, 3i Group, Apax Partners, HBM Partners and TVM Capital Life Science. Who are Newron Pharmaceuticals's …See details»
Newron Announces 2022 Financial Results and Provides Outlook
Mar 14, 2023 MILAN-- ( BUSINESS WIRE )-- Newron Pharmaceuticals S.p.A. (“Newron”) (SIX: NWRN, XETRA: NP5), a biopharmaceutical company focused on the development of novel …See details»
Regulatory News | Newron Pharmaceuticals
Apr 1, 2025 Download view online Jan 09 2025 Newron and Myung In Pharm announce license agreement for evenamide in South Korea Download View online Download (German) View …See details»
Newron Announces 2021 Financial Results and Provides Outlook …
Mar 15, 2022 Newron Pharmaceuticals (SIX: NWRN, XETRA: NP5) announces 2021 financial results and provides outlook for 2022. Conference call today at 10:00 AM EDT.See details»
The Waterloo Regional Health Network Board of Directors is …
Apr 1, 2025 In preparation for the April 01, 2025, merger of St. Mary’s General Hospital and Grand River Hospital, Ron Gagnon was unanimously selected by the Board to lead the new …See details»